Skip to content 
Last reviewed: September 10, 2026.
A pet-health company should bring small-batch spot-on filling in-house when recurring demand, frequent campaigns, product-control needs and avoidable contract-manufacturer setup or lead-time costs can support the annualized equipment, facility, labor, quality and changeover burden. Contract manufacturing is usually the lower-risk starting point when demand is uncertain, campaigns are infrequent, the company lacks an appropriate facility or quality organization, or the external partner provides capabilities that would be costly to reproduce.
There is no universal break-even batch size. The decision depends on saleable doses per SKU, campaign frequency, package complexity, changeover validation, yield, release testing, inventory, lead time and the owner's quality responsibilities. Use the worksheet below with your own operating inputs. If you are also evaluating an equipment upgrade, the related drop-filling equipment ROI discussion provides additional investment context.
Quick answer: Build two annual landed-cost models on the same demand and quality scope. For the CMO case, include conversion price, batch setup and minimums, testing and release, technology transfer, oversight, freight, inventory and change costs. For the in-house case, include annualized equipment and facility cost, operators, utilities, maintenance, quality and validation, changeover labor and downtime, startup loss, rejects and inventory. Compare cost per saleable dose, cash timing, lead time, capacity headroom and risk. Confirm the in-house assumptions with actual pipette and product samples before committing.
1 Define the Decision Unit Before Comparing Quotations
Direct answer: Compare the annual cost and risk of delivering one saleable, released spot-on dose for the same products, packages and markets.
Start with demand by SKU, target fill, pipette or applicator type, seal method, number of doses per sale pack, batch size, campaigns per year, forecast range and required release date. Separate base demand from launch, upside and downside cases. A single annual total can hide the changeover burden created by many low-volume SKUs.
Define which operations are included in both options: bulk preparation, filtration, transfer, filling, sealing or closing, leak testing, coding, secondary packing, testing, release, storage and distribution. If the CMO quotation includes cartoning but the equipment quotation ends at filled pipettes, add the missing operations before comparing cost.
Use saleable released doses as the denominator. Input doses can be lost during setup, sampling, seal development, planned rejects, reconciliation and batch-end residual. Do not assume one loss percentage for every formula and pack. Record the measured or contracted value for each route and expose unknowns as ranges.
| Decision input | Unit | Why it matters |
|---|---|---|
| Annual demand by SKU | Saleable doses | Sets campaigns, capacity and working capital |
| Batch size and frequency | Doses and batches/year | Drives setup, changeover, testing and release events |
| Package format | Pipette/applicator and seal | Changes tooling, defect risk and test scope |
| Required lead time | Calendar days | Affects service, inventory and schedule control |
| Scope boundary | Included operations | Prevents unlike quotation comparison |
2 Use a Practical Make-or-Buy Rule
Direct answer: In-house production becomes more attractive when utilization is credible and the value of schedule, process and knowledge control exceeds the fixed ownership burden.
Contract manufacturing remains attractive when volume is low or volatile, only occasional campaigns are needed, several formats require capabilities the owner does not possess, or the product can share a qualified CMO platform efficiently. It converts some fixed cost into variable cost and can shorten the path to initial supply when the transfer and quality agreement are well managed.
In-house production becomes attractive when annual campaigns are frequent, CMO minimums create overproduction, setup charges repeat across many SKUs, queue time damages service, change requests move slowly, product knowledge is strategically important, or a compact line can support several validated products without excessive changeover loss.
The decision is not only a cost-per-dose comparison. Add a weighted evaluation for control, confidentiality, supply continuity, release responsiveness, forecast error and internal capability. Keep weights visible and approved by the decision team instead of hiding judgment in the final score.
3 Calculate the Contract Manufacturing Landed Cost
Direct answer: Treat the CMO quotation as one input and add every owner-side cost required to transfer, oversee, release and receive the product.
List the unit conversion charge, minimum batch or campaign charge, setup and changeover, line trial, tooling, component handling, cleaning validation, stability or method transfer, routine laboratory testing, release, deviation investigation, change control, storage, freight, insurance, customs where relevant, scrap disposition and annual quality review. Classify each as one-time, per batch, per SKU, per year or per dose.
Add the owner's continuing work: forecasting, purchase orders, component supply, technical support, quality agreement, audits, document review, deviation and complaint oversight, release responsibility and safety-stock management. FDA's cross-center quality-agreement guidance includes the Center for Veterinary Medicine and explains that quality agreements should define responsibilities; outsourcing does not erase applicable CGMP responsibilities.
Model minimums explicitly. If the CMO bills a minimum campaign quantity above demand, include the full billed cost in the numerator and use saleable doses supported by the demand plan as the denominator. Excess stock can expire or consume working capital. Do not assume all excess is usable; use the product's actual shelf-life and demand plan.
| CMO cost driver | Frequency | Input source |
|---|---|---|
| Conversion and package operations | Per dose or lot | CMO commercial quotation |
| Setup, cleaning and changeover | Per campaign / SKU | CMO quotation and quality agreement |
| Testing, review and release | Per batch | Quality and laboratory scope |
| Transfer, tooling and validation | One-time and change-driven | Technical-transfer plan |
| Owner oversight and audits | Annual and event-driven | Internal time and travel estimate |
| Freight, inventory and obsolescence | Per shipment / annual | Supply-chain model |
4 Calculate the In-House Annual Ownership Cost
Direct answer: Annualize capital over the approved financial horizon and add the full recurring manufacturing and quality organization.
Capital may include preparation and holding vessels, transfer, spot-on filling and sealing equipment, package feeders, leak or seal checks, coding, secondary packing, utilities, facility modification, environmental controls where required, laboratory equipment, installation, qualification, tooling, initial spares and training. Use finance-approved depreciation, lease or cash-flow treatment instead of a generic payback convention.
Recurring cost includes operators, supervisors, maintenance, engineering, quality, validation, laboratory testing, utilities, cleaning agents, parts, calibration, software, waste, facility overhead, insurance, audits and periodic requalification. Add the internal time required to plan, document, investigate and release each batch.
Keep unused capacity visible. A line that can produce the annual demand in a few weeks still carries a full-year ownership cost unless it is credibly shared with other products. Shared capacity should be allocated through a stated rule and should not double-count the same hours in several investment cases.
5 Model Changeover as Cost, Capacity and Quality Work
Direct answer: Multiply the complete released-changeover time and loss by annual campaign frequency, not only the mechanical adjustment time.
For each product and format pair, estimate line clearance, reconciliation, draining, disassembly, contact and non-contact cleaning, sampling, laboratory wait where it blocks the line, drying, reassembly, format setup, recipe and code verification, first-off units and QA release. Separate labor hours from blocked equipment hours because they affect different cost pools.
Add cleaning media, replacement single-use parts, rejected startup units and product left in the path. Use product-pair data or ranges, supported by the site's validated changeover procedure. Review the relevant dosage forms and equipment interfaces in the KING PACK pharmaceutical and veterinary solution overview when defining which operations belong inside the cost model.
Campaigning can reduce changeover frequency but increase inventory and exposure to forecast error. Model both. A lower annual changeover count is beneficial only if the resulting stock remains saleable and does not extend beyond approved holding, packaging or shelf-life constraints.
6 Convert Capacity into Credible Saleable Output
Direct answer: Use demonstrated sustained output and available production hours after planned activities, then apply yield once without double counting.
Calculate scheduled hours from planned production days, shifts and hours per shift. Subtract the hours blocked by line clearance, cleaning, setup, sampling, planned maintenance and known release constraints. Required sustained good-dose output per hour equals demand divided by the resulting available production hours. Check whether the slowest connected operation can sustain that rate in a product-package trial.
Distinguish availability, speed loss and quality loss. If the model uses an OEE assumption that already includes these losses, do not subtract the same stops and rejects again. For an early decision, use low, base and high cases with clearly labeled assumptions and later replace them with trial or production evidence.
The KING PACK filling and capping line platform can provide architecture context for integrated handling. A spot-on project still requires its actual pipette, formulation, dosing, sealing and leak-test boundary before a sustainable rate can be confirmed.
7 Build the TCO Worksheet Without Invented Prices
Direct answer: Use buyer quotations and internal rates, calculate both annual totals and cost per saleable dose, and display the break-even volume as a range.
For contract manufacturing, annual landed cost equals fixed annual CMO and oversight cost plus the sum of per-batch setup, testing and changeover cost times annual batches, plus per-dose conversion and logistics cost times ordered doses, plus inventory and risk costs selected by the buyer. For in-house production, annual ownership cost equals annualized capital and facility cost plus fixed labor and quality cost, plus batch and changeover cost, plus variable production cost, product loss and inventory cost.
Cost per saleable dose equals annual landed cost divided by saleable released doses. Break-even demand can be estimated where the fixed and variable cost structure is stable, but SKU count and campaign frequency often change as volume changes. Use a sensitivity table across demand, campaigns and changeover hours instead of presenting one false-precision volume.
Keep non-cash depreciation, cash investment, working capital and risk adjustments separate so finance can use the model correctly. Label all assumptions, currencies, tax treatment, horizon and discount method. This article provides the structure, not a universal financial recommendation.
| Worksheet line | In-house formula input | CMO formula input |
|---|---|---|
| Fixed annual cost | Annualized equipment, facility, core team | Program fees, audit and owner oversight |
| Per-batch cost | Setup, cleaning, testing, release | Setup, minimum, testing and release |
| Per-dose cost | Materials, labor variable, utilities, packaging | Conversion, handling and logistics |
| Loss and inventory | Startup, rejects, residual, stock | Minimum overbuy, transit and safety stock |
| Saleable denominator | Released good doses | Released received doses needed |
| Decision outputs | Cost/dose, cash, capacity, lead time | Cost/dose, working capital, lead time |
8 Compare Lead Time and Supply Risk
Direct answer: Measure end-to-end elapsed time and the cost of delay or excess inventory rather than assuming that one route is always faster.
The CMO path can include forecast lock, purchase-order approval, component arrival, queue time, setup, manufacturing, laboratory testing, document review, release, freight and receipt. The in-house path can reduce queue and transport time after qualification, but it adds internal scheduling, material readiness, testing and maintenance constraints.
Model normal lead time, variability and recovery after a deviation or demand spike. A CMO may offer redundant capacity; an in-house compact line may provide immediate control but become a single point of failure. Ask both routes how alternate tooling, critical spares, backup power, substitute laboratories and emergency campaigns are handled.
Translate risk only where the buyer has evidence. Examples include lost contribution from a stockout, expedited freight, excess inventory write-off or overtime for a recovery campaign. Keep qualitative risks beside the financial model when they cannot be valued credibly.
9 Keep Quality Ownership Visible in Both Routes
Direct answer: A quality agreement allocates activities and communication; it does not eliminate the legal or quality responsibilities that apply to either party.
FDA's Contract Manufacturing Arrangements for Drugs guidance, issued with CVM participation, describes how owners and contract facilities can define quality responsibilities. For EU veterinary medicinal products, Commission Implementing Regulation (EU) 2025/2091 has applied since July 16, 2026. Article 43 addresses outsourced activities, including written responsibilities, contractor suitability, audits, access to records and control of subcontracting. Confirm the requirements for the product and destination market when preparing the agreement.
For the CMO route, define batch documentation, release sequence, deviations, OOS results, changes, complaints, recalls, audits, subcontracting, data access, retention, samples, specifications, methods and communication timelines. For the in-house route, confirm that the owner can staff and sustain these same functions directly.
Do not equate an external audit, certificate or past inspection with product-specific readiness. Assess the exact facility, equipment path, package format, analytical scope and capacity. For in-house investment, include site registration, inspection readiness and market-specific requirements in the project plan where applicable.
10 Run a Pilot and Sample Test Before Committing
Direct answer: Use representative product and pipettes to convert uncertain rate, loss, sealing and changeover assumptions into evidence.
Provide formulation properties, target dose, batch size, pipette drawings and tolerances, film or material data, sealing window where known, coding requirements and expected campaign pattern. Test product feed, dosing, air and drip behavior, seal-zone cleanliness, seal formation, leak-test approach, component feeding, rejects, planned stops and batch-end residual.
Run at the proposed minimum and normal batch condition. Record setup quantity, first acceptable unit, sustained good-unit output, product residual, reject reasons, changeover steps and time. A short favorable demonstration cannot establish annual capacity, but it can replace several broad assumptions with project-specific ranges.
Ask the equipment supplier for product-path and format drawings, utility and layout data, spare parts, cleaning access, software and recipe description, FAT protocol and qualification-support scope. Ask the CMO for the equivalent process, quality, capacity and change-control evidence so the decision compares like with like.
| Trial question | Evidence | TCO line affected |
|---|---|---|
| How many units and minutes to first acceptable output? | Startup record | Setup labor, loss and blocked time |
| Can the line sustain the required good-unit rate? | Timed run and reject log | Capacity and labor |
| Does sealing remain clean after stops? | Seal and leak-test observations | Reject and quality risk |
| How much product remains at batch end? | Residual measurement or justified estimate | Yield and waste |
| How long is the released changeover? | Witnessed protocol and open actions | Campaign capacity and cost |
11 Make the Decision Through a Gated Review
Direct answer: Approve the route only after commercial, technical, quality, supply and finance assumptions use the same demand and scope.
Gate 1 confirms product, package, market, demand and forecast cases. Gate 2 confirms the CMO's scope, minimums, quality agreement and capacity evidence. Gate 3 confirms the in-house equipment concept, facility gap, staffing, validation plan and sample results. Gate 4 compares total annual cost, cash, cost per saleable dose, lead time, capacity and risk.
Record the decision, key assumptions and triggers for reassessment. Examples include demand crossing a band, a new SKU, a packaging change, CMO price or lead-time change, facility expansion, repeated service failure or the need to protect process knowledge. Revisit the model rather than treating make-or-buy as permanent.
Hybrid strategies can be valid. A company may keep launch or overflow batches with a qualified CMO while installing a compact line, or retain a backup contractor after internal transfer. Model duplicated validation, inventory and oversight honestly; a hybrid route is not automatically cheaper.
12 Review a Compact In-House Option with KING PACK
Direct answer: KING PACK can translate demand, batch, SKU and package inputs into a preliminary spot-on line configuration and sample-test plan for the buyer's TCO model.
KING PACK Machinery is a China-based manufacturer of pharmaceutical, veterinary, cosmetic and liquid filling and packaging equipment, with core solutions covering tube filling and sealing, vacuum emulsifying, liquid filling, pet spot-on filling and prefilled syringe production systems.
For a small-batch spot-on project, the review can cover bulk feed, fill range, pipette handling, sealing or closure operation, coding, inspection, reject logic, product recovery, changeover, cleaning access, layout, utilities, documentation and FAT. The final business case remains dependent on buyer quotations, internal rates, facility requirements and quality strategy.
Send annual demand by SKU, batch and campaign plan, product properties, package drawings and samples, current outsourced scope and charges that can be disclosed, lead-time needs, cleaning assumptions and required test methods through the KING PACK contact page. KING PACK can return configuration and test inputs for the buyer's capacity and TCO worksheet.
Frequently Asked Questions
When should small-batch spot-on filling move in-house?
Consider in-house production when recurring demand and frequent campaigns can support fixed ownership cost and when schedule, process or knowledge control has material value. Confirm the model with project-specific sample evidence.
Is there a standard break-even batch size?
No. Break-even depends on demand by SKU, campaigns, CMO minimums, changeover time, yield, facility and labor cost, quality work, package format and financing assumptions.
What should be included in CMO landed cost?
Include conversion, minimums, setup, changeover, testing, release, transfer, tooling, quality oversight, audits, freight, storage, inventory, deviations and owner-side work.
What should be included in in-house TCO?
Include annualized equipment and facility cost, labor, maintenance, utilities, quality and validation, testing, cleaning, changeover, startup loss, rejects, residual product, spares and inventory.
How does SKU count affect the decision?
More low-volume SKUs can multiply setup, clearance, cleaning, testing and release events. Model campaigns by product and format rather than dividing total demand by one line rate.
Does outsourcing transfer quality responsibility to the CMO?
No. A quality agreement should allocate activities and communication, but each party retains the responsibilities that apply to it. Product owners must maintain appropriate oversight and release controls.
What should a spot-on line sample test prove?
It should characterize product feed, dose, air and drip behavior, seal-zone cleanliness, seal or closure result, leak-test approach, component handling, rejects, stops, batch-end residual and changeover.
What inputs should be sent to KING PACK for a preliminary TCO review?
Send annual demand by SKU, batches and campaigns, formulation behavior, package drawings and samples, target fill, outsourced scope, lead-time needs, cleaning plan and acceptance methods.
